Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanomaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether gut microbiome composition, measured before treatment, is associated with response to immune checkpoint inhibitors in metastatic melanoma. Researchers used metagenomic shotgun sequencing on stool samples collected prior to treatment. The analysis specifically corrected for known confounders of gut microbiome composition, including age, BMI, and antibiotic use, which prior studies had often overlooked. Both taxonomic abundance and survival outcomes were assessed in relation to checkpoint inhibitor response.
Who was studied?
The study included 25 patients with unresectable metastatic melanoma who were treated with immune checkpoint inhibitors. Of these, 12 were classified as responders and 13 as non-responders. Pre-treatment stool samples were freshly frozen and analyzed from each of these patients.
What were the most important findings?
Alpha-diversity and overall bacterial prevalence did not differ significantly between responders and non-responders. However, after correcting for confounders in a zero-inflated multivariate analysis, 68 taxa showed differential abundance between the two groups. Carriership of Streptococcus parasanguinis was associated with longer overall survival, and carriership of Bacteroides massiliensis was associated with longer progression-free survival. In contrast, carriership of an unclassified Peptostreptococcaceae species was associated with shorter overall survival.
What are the greatest implications of this study?
The findings suggest that simple measures like overall diversity are insufficient to explain gut microbiome links to checkpoint inhibitor outcomes in melanoma, and that confounder-adjusted, species-level analysis reveals associations that broader measures miss. Identifying specific taxa tied to survival, such as Streptococcus parasanguinis and Bacteroides massiliensis, points to candidate biomarkers or mechanistic targets for future investigation. This approach, accounting for confounders like antibiotic use, age, and BMI, may help explain why prior studies lacked consensus on which taxa matter for treatment response.